-
公开(公告)号：US20240042002A1
公开(公告)日：2024-02-08
申请号：US17789451
申请日：2020-12-31
申请人： ANTAGONIS , UNIVERSITE DE VERSAILLES-ST QUENTIN EN YVELINES , ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
IPC分类号： A61K39/085 , A61K39/40 , A61P31/04 , G01N33/569 , C12Q1/18
CPC分类号： A61K39/085 , A61K39/40 , A61P31/04 , G01N33/56938 , C12Q1/18 , G01N2333/31 , G01N2469/10
摘要： The present invention relates to an immunogenic composition comprising at least one Staphylococcus aureus antigen, wherein said antigen is a polypeptide having at least 80% identity with the SdrH-like polypeptide of SEQ ID NO: 8, Nuc of SEQ ID
NO: 4, or LukG of SEQ ID NO: 12, an immunotherapeutic composition comprising a polyclonal antibody which selectively binds to at least one of said antigens, and an in vitro method of identifying an antigen conferring protection against disease caused by S. aureus in a subject.-
公开(公告)号：US20180371043A1
公开(公告)日：2018-12-27
申请号：US16044491
申请日：2018-07-24
发明人： Andreas Kungl
CPC分类号： C07K14/5421 , A61K38/00 , C07K14/521 , C07K14/523 , C07K2319/31
摘要： The present invention relates to novel monomeric fusion proteins derived from human GAG binding proteins such as chemokines with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type GAG binding proteins, which are highly selectively competitive and are of increased bioavailability, and to their use for prevention or treatment of pathological cell movement as in metastasis.
-
公开(公告)号：US10047133B2
公开(公告)日：2018-08-14
申请号：US15113394
申请日：2015-01-22
发明人： Andreas Kungl
摘要： The present invention relates to novel monomeric fusion proteins derived from human GAG binding proteins such as chemokines with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type GAG binding proteins, which are highly selectively competitive and are of increased bioavailability, and to their use for prevention or treatment of pathological cell movement as in metastasis.
-
公开(公告)号：US20220281934A1
公开(公告)日：2022-09-08
申请号：US17631868
申请日：2020-08-28
发明人： Andreas KUNGL
摘要： Herein provided is a novel recombinant CXCL10 polypeptide with increased glycosaminoglycan (GAG) binding affinity compared to wild type CXCL10 and increasing T-cell mobilization and its use for preventing or treating inflammatory and immuno-logical disorders and auto-immune diseases.
-
公开(公告)号：US10703790B2
公开(公告)日：2020-07-07
申请号：US16044491
申请日：2018-07-24
发明人： Andreas Kungl
摘要： The present invention relates to novel monomeric fusion proteins derived from human GAG binding proteins such as chemokines with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type GAG binding proteins, which are highly selectively competitive and are of increased bioavailability, and to their use for prevention or treatment of pathological cell movement as in metastasis.
-
6.发明申请NOVEL GLYCOSAMINOGLYCAN-ANTAGONISING FUSION PROTEINS AND METHODS OF USING SAME 审中-公开新型谷氨酰胺凝集素拮抗融合蛋白及其使用方法公开(公告)号：US20170058012A1
公开(公告)日：2017-03-02
申请号：US15113394
申请日：2015-01-22
发明人： Andreas Kungl
CPC分类号： C07K14/5421 , A61K38/00 , C07K14/521 , C07K14/523 , C07K2319/31
摘要： The present invention relates to novel monomeric fusion proteins derived from human GAG binding proteins such as chemokines with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type GAG binding proteins, which are highly selectively competitive and are of increased bioavailability, and to their use for prevention or treatment of pathological cell movement as in metastasis.
摘要翻译： 本发明涉及与野生型GAG结合蛋白相比，衍生自人GAG结合蛋白的新型单体融合蛋白，例如具有增加的糖胺聚糖（GAG）结合亲和力的趋化因子，并且与野生型GAG结合蛋白相比具有高选择性竞争性，并具有 增加的生物利用度，以及它们在转移中用于预防或治疗病理性细胞运动的用途。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.011 秒)
